Novel Cellular Therapeutic Approach for ALS Gets FDA Clearance for First-in-Human Trials

Posted byclientekdevPosted instem cell research

http://www.businesswire.com/news/home/20150604005355/en/Cellular-Therapeutic-Approach-ALS-FDA-Clearance-First-in-Human#.VXDOmsp0yUk

SALT LAKE CITY–(BUSINESS WIRE)–Q Therapeutics, Inc., a clinical-stage developer of novel cellular therapies for central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for the initiation of Phase 1/2a clinical trials of its Q-Cells® product in patients with amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig’s disease, ALS is a devastating condition caused by degeneration of motor neurons, the nerve cells in the brain and spinal cord that …